Home News DGAP-News: MPH Mid Pharma Holding AG:

DGAP-News: MPH Mid Pharma Holding AG:

48
0

Release of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The content of the The issuer / publisher is solely responsible.
—————————————————————————
MPH Mid Pharma Holding AG: Figures from the first Quarter of 2010 confirm sustainable revenue and earnings growth in the current fiscal year
The MPH Mid Pharma Holding AG, which at 06.03.2009 founded, was today presented its preliminary results at 31 March 2010 before.
The MPH group generated in the first Quarter 2010 sales of EUR of € 26.4 million and a net income of EUR € 2.81 million. Profits before interest and tax (EBIT) stood at 3.28 million Euro. Earnings before interest, taxes, depreciation and amortization (EBITDA) stood at € 3.33 million.
The performance of MPH group was also in the first Quarter of 2010 in full Founded in 2005 by the scope and operational working 100% Daughter company HAEMATO PHARM AG, Schönefeld intended. These revenues over the first three months of 2010 a turnover of 26.4 million € (Previous year: € 8.6 million) and a net income of EUR € 2.83 million (previous year: € 0.56 million). The profit before interest and taxes (EBIT) amounted to € 3.3 million (previous year: € 0.7 million). Profit before Interest, taxes, depreciation and amortization (EBITDA) stood at 3.36 million euros (previous year: € 0.75 million).
More and more pharmacists, physicians and patients rely on EU imported original and generic drugs. Therefore expects the Company for the current fiscal year 2010 with a Sales increase to over 100 million euros.
To date 03/31/2010 has increased the number of Employees in the MPH group within the last year from 17 to 46
About the MPH Mid Pharma Holding AG: Berlin MPH Mid Pharma AG has a strategic focus on Growth segments concentrated in the pharmaceutical market. Core competencies are the Licensing, acquisition and processing of pharmaceutical products. By Subsidiary HAEMATO PHARM AG are currently the business Development and approval of generics, and licensing and import of European brand drugs covered. The product range includes both the oncology area and the therapeutic areas of HIV, Neurology, cardiovascular, and rheumatism, and is continuously expanded. The MPH Mid Pharma Holding AG since 01.09.2009 in Unofficial Market (Open Market) at the Frankfurt Stock Exchange.
Key Figures of the MPH Mid Pharma Holding AG: Share capital: EUR 38.05 million Quoted Share class: Ordinary bearer preference shares Number of outstanding preferred shares: 19.025 million ISIN: WKN DE000A0NF697: A0NF69 ticker symbol: 93MV